Scientific Online Resource System

Varna Medical Forum

Expression of hepatic HMGB1 levels in fructose-induced fatty liver

Kameliya Bratoeva, Eleonora Dimitrova, Nikolay Conev, Javor Kashlov, Elena Panajotova, George Stoyanov, Mariya Radanova, Ivan Donev

Abstract

The study of the processes leading to hepatocellular cell death is important for clinical practice to assess the severity of hepatic impairment as well as for the application of effective interventions to prevent it. Observations show that both cell death processes - apoptosis and necrosis are activated at certain stages of the progression of non-alcoholic fatty liver disease from hepatic steatosis, steatohepatitis and cirrhosis. Currently, the most promising non-invasive specific method for detecting necrotic cell death is non-histone DNA-binding protein with high mobility Group B1 (HMGB1). The aim of this study was to investigate the levels of HMGB1 expression and their relationship to hepatic injury and apoptosis activity in rat liver with fructose-induced metabolic syndrome. The results showed data for metabolic syndrome, microvascular steatosis, statistically reduced levels of HMGB1, an increased ratio of Bax/Bcl2 apoptotic proteins in fructose fed rats.

Keywords

HMGB1; fatty liver; apoptosis; fructose

Full Text


References

Братоева K, Донев И, Цанева М, Бекярова Г. Oксидативен стрес и механизъм на хепатоцитно оцеляване при фруктозо-индуцирана чернодробна стеатоза. Наука и младост- сборник научни съобщения от конкурсна сесия 2013 г.;1: 199-203.

Цанева М. Морфофункционално състояние на ендокринните клетки на стомаха при някои форми гастрити (Helicobacter pylori – асоцииран гастрит, реактивен гастрит при дуоденагастралн рефлукс и остър експериментален гастрит с ацетилсалицилова киселина), Дисертация, 1999; 199 стр.

Abdelmalek M. F., Diehl A. M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. North Am. 2007; 91:1125-1149.

Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002, 18;346(16):1221-31.

Botezelli JD, Mora RF, Dalia RA, Moura LP, Cambri LT, Ghezzi AC et al. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis. 2010 ;14;9:116.

Bratoeva K, G Bekyarova, Y Kiselova, D Ivanova. Effect of Bulgarian herb extracts of polyphenols on metabolic disorders-induced by high fructose diet. Trakia Journal of Sciences, 2010; 8(2): 56-60.

Bratoeva K, Bekyarova G. Effect of extract of selected Bulgarian herbs (HA-1) on high fructose diet- induced hepatic injury in rats. Balkan Medical Union,2011; 46 (4), 107-111.

Bratoeva K, M Radanova, Merdzhanova A, Donev I. Protective Role of S-Adenosylmethionine Against Fructose-Induced Oxidative Damage in Obesity. Journal of Mind and Medical Sciences 2017; 4 (2): 163-171.

Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004; 114(2):147-52.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95.

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74.

Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010 ;16(42):5286-96.

Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21(1):27-41.

Delarue J, Normand S, Pachiaudi C, Beylot M, Lamisse F, Riou JP. The contribution of naturally labelled 13C fructose to glucose appearance in humans. Diabetologia. 1993; 36(4):338-45.

Ehrmann J Jr, Galuszková D, Ehrmann J, Krc I, Jezdinská V et al. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. Pathol Oncol Res. 2000; 6(2):130-5.

Ferreira DM, Castro RE, Machado MV, Evangelista T, Silvestre A, Costa Aet al. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia. 2011; 54(7):1788-98.

Figlewicz DP, Ioannou G, Bennett Jay J, Kittleson S, Savard C, Roth CL.Effect of moderate intake of sweeteners on metabolic health in the rat. Physiol Behav. 2009; 98(5):618-24.

Guicciardi ME and Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005; 54(7): 1024-1033.

Hotchkiss R, Strasser A, Jonathan E, McDunn. Cell Death. N Engl J Med 2009; 361:1570-1583.

Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006 ;49(5):450-65.

Klune JR, Dhupar R, Cardinal J, Billiar TR, and Tsung A. HMGB1: Endogenous Danger Signaling. Mol Med. 2008; 14(7-8): 476-484.

Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med. 2003; 9 : 37-45.

Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012; 145754.

Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004; 164 : 441-9.

Samuel VT, Liu ZX, Qu X , Elder BD, Bilz S, Befroy B et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 2004; 279: 32345-32353.

Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418(6894):191-5.

Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009; 119(5):1322-34.

Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005; 33(3):564-73.

Tevar A, Clarke C, Wang J, Rudich SM, Woodle S, Lentsch A et al. Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg. 2010; 210(4):515-26.

Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006; 131(3):934-45.

Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008 May;134(6):1682-98.




DOI: http://dx.doi.org/10.14748/vmf.v7i1.5014

Refbacks

Font Size


|